Cancer News and Research

Latest Cancer News and Research

Four live cases using Toshiba's Infinix-i vascular X-ray systems to be showcased at NCVH

Enabling physicians to transition between cardiac and peripheral work seamlessly during a single procedure, Toshiba America Medical Systems, Inc.'s Infinix-i vascular X-ray systems facilitate better physician workflow and support improved patient care.

6 Jun 2012

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

Patients with active psoriatic arthritis receiving the interleukin (IL)-12/23 inhibitor STELARA (ustekinumab) experienced significant improvements in signs and symptoms of the disease, according to new findings presented today from a Janssen Research & Development, LLC, (Janssen)-sponsored investigational study.

6 Jun 2012

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the open-label extension of the Phase 3 ABILITY-1 investigational study of HUMIRA (adalimumab), which assessed the improvement in signs and symptoms of disease for patients with active axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage.

6 Jun 2012

Patients with type 2 diabetes have 20% increased risk of blood cancers

Patients with type 2 diabetes have a 20 percent increased risk of developing blood cancers, such as non-Hodgkin lymphoma, leukemia and myeloma, according to a new meta-analysis led by researchers at The Miriam Hospital.

6 Jun 2012

Cardio-protective drug during cancer treatment may prevent heart damage in children

About 75 percent of children with leukemia who take chemotherapy face life-threatening heart problems as they age, but an international study led by a University of Rochester Medical Center investigator shows that giving a cardio-protective drug during cancer treatment may prevent the damage.

6 Jun 2012

bioTheranostics’ CancerTYPE ID molecular test improves overall survival for patients with CUP

bioTheranostics, developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced study results showing that tumor profiling with its CancerTYPE ID molecular test helped guide site-specific chemotherapy and improve overall survival for patients with carcinoma of unknown primary site.

6 Jun 2012

UCSF's ACT program helps amputees reach their athletic goals

Carlos Gonzalez stands out from an athletic group gathered on a grassy field at the UCSF Mission Bay campus. The gregarious 32-year-old sports a stylish fauxhawk and walks with a confident yet understated swagger. He's training to become a mixed martial arts (MMA) fighter.

6 Jun 2012

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for the Company's oral anticancer compound, perifosine, in multiple myeloma, have been published in the online May 2012 issue of the British Journal of Haematology.

6 Jun 2012

Firefly surgical technology sheds new light on kidney cancers

A surgical technology called Firefly is shedding new light on kidney cancers and helping doctors at MedStar Georgetown University Hospital remove tumors more safely and more efficiently while sparing the rest of the healthy kidney.

6 Jun 2012

BioLineRx receives two U.S. patent allowances for BL-1021 to treat neuropathic pain

BioLineRx, a biopharmaceutical development company, announced today that two Notices of Allowance have been issued by the United States Patent and Trademark Office (USPTO) for BL-1021, an orally available small molecule for treating neuropathic pain.

6 Jun 2012

NTNU’s EIR software to be showcased at 7th World Research Congress of the EAPC

What happens when doctors cannot cure a disease? What is the best way to make patients comfortable and have the best quality of life possible in the time they have left? Researchers at the Norwegian University of Science and Technology (NTNU) have developed software that can be used with an iPad or other tablet to help record patient pain levels to help doctors in developing further treatment.

6 Jun 2012

VGXI, OncoSec partner to produce interleukin-12 plasmid DNA

OncoSec Medical Inc., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announced today that the Company has entered into an exclusive cGMP manufacturing agreement with VGXI Inc. (VGXI) for the production of interleukin-12 plasmid DNA.

6 Jun 2012

BioInvent, ThromboGenics to regain global rights to TB-403 from Roche

ThromboGenics NV and co-development partner BioInvent International announce today that they will regain global rights to TB-403 from Roche.

6 Jun 2012

Transgenomic introduces ICE COLD-PCR mutation detection technology

Transgenomic, Inc. today announced the commercial launch of its ICE COLD-PCR mutation detection technology, a breakthrough technology enabling unmatched sensitivity and complete DNA mutation detection using the standard sequencing equipment already installed in laboratories around the world.

6 Jun 2012

Bayer announces updated data from radium-223 dichloride Phase III trial on CRPC

Bayer HealthCare today announced updated data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial for its investigational drug radium-223 dichloride in men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases.

6 Jun 2012

Study identifies existence of an antitumor molecule that originates within SMYD3 oncogene

A common point in all human tumors is that they produce an activation of oncogenes, genes that cause cancer and they also cause a loss of function of the protective genes, called anti-oncogenes or tumour suppressor genes. Normally both categories of anticancer and procancer genes are in different regions of our chromosomes.

6 Jun 2012

High pollution increases risk of repeated heart attacks by over 40%

Air pollution, a serious danger to the environment, is also a major health risk, associated with respiratory infections, lung cancer and heart disease. Now a Tel Aviv University researcher has concluded that not only does air pollution impact cardiac events such as heart attack and stroke, but it also causes repeated episodes over the long term.

6 Jun 2012

New immune response data from Generex’s AE37 Phase II trial on breast cancer

Generex Biotechnology Corporation announced today that new immune response data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine undertaken by Generex wholly-owned subsidiary Antigen Express, Inc. was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2, 2012 in Chicago, IL.

6 Jun 2012

e+CancerCare announces major partnership with OncoLogics

e+CancerCare, a leading operator of outpatient cancer care centers that combines clinical and service expertise to better manage patients, today announced a major partnership with OncoLogics, Inc., a Lafayette-based radiation oncology group.

6 Jun 2012

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Exelixis, Inc. today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases.

6 Jun 2012